Idorsia Reports Positive Phase 2 Results for Daridorexant in Pediatric Insomnia

Idorsia reported positive results from a Phase 2 study of daridorexant for pediatric insomnia, involving 165 participants aged 10 to 17. The 50 mg dose increased sleep time by an average of 50 minutes, and 64 minutes in children with neurodevelopmental disorders, with a safety profile similar to that in adults. The company plans to initiate a Phase 3 study in the second half of next year. Daridorexant is currently marketed as Quviviq for adults in North America and Europe.